Improving treatment outcomes for patients with advanced bile duct cancer.
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)
This study is looking at a new way to treat patients with advanced bile duct cancer by comparing a standard chemotherapy with an added treatment delivered directly to the liver, to see which helps people live longer.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10897008 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for patients with advanced intrahepatic cholangiocarcinoma (IHC), a type of bile duct cancer that often has a poor prognosis. The study compares the effectiveness of a combination of standard chemotherapy drugs, gemcitabine and oxaliplatin, with an additional regional chemotherapy agent, floxuridine, delivered directly to the liver. Patients will be randomly assigned to receive either the standard treatment or the combination treatment to determine which is more effective in improving survival rates. The study aims to provide better treatment options for patients whose cancer cannot be surgically removed.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with unresectable intrahepatic cholangiocarcinoma who have limited treatment options.
Not a fit: Patients with resectable intrahepatic cholangiocarcinoma or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment options for patients with advanced bile duct cancer.
How similar studies have performed: Previous studies have shown promising results with similar combination therapies, indicating potential for success in this approach.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Jarnagin, William Robert — Sloan-Kettering Inst Can Research
- Study coordinator: Jarnagin, William Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.